What’s Ahead for BioSig Technologies, Inc. (BSGM) After Today’s Significant Decline?

BioSig Technologies, Inc. (NASDAQ:BSGM) Logo

The stock of BioSig Technologies, Inc. (NASDAQ:BSGM) is a huge mover today! The stock decreased 10.32% or $0.97 during the last trading session, reaching $8.43. About 528,105 shares traded or 380.30% up from the average. BioSig Technologies, Inc. (NASDAQ:BSGM) has risen 61.18% since May 14, 2018 and is uptrending. It has outperformed by 56.81% the S&P500.
The move comes after 8 months negative chart setup for the $171.93 million company. It was reported on May, 14 by Barchart.com. We have $7.67 PT which if reached, will make NASDAQ:BSGM worth $15.47M less.

More notable recent BioSig Technologies, Inc. (NASDAQ:BSGM) news were published by: Time.com which released: “China Criticizes U.S. Advice to ‘Exercise Increased Caution’ While Traveling – TIME” on January 04, 2019, also Seekingalpha.com with their article: “How BioSig Technologies Is Positioned To Change The Electrophysiology Market – Seeking Alpha” published on March 23, 2016, Globenewswire.com published: “BioSig Appoints John Kowalski to Lead Commercialization of PURE EP – GlobeNewswire” on February 05, 2019. More interesting news about BioSig Technologies, Inc. (NASDAQ:BSGM) were released by: Time.com and their article: “Virginia Sets Up First Historical Marker for Lynching Victim – TIME” published on April 09, 2019 as well as Time.com‘s news article titled: “Mexico’s Top Cop Says He Was an Undocumented Worker in U.S. – TIME” with publication date: April 02, 2019.

BioSig Technologies, Inc., a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. The company has market cap of $171.93 million. The Company’s product is PURE EP System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during electrophysiology studies and catheter ablation procedures. It currently has negative earnings. It is also developing a library of software tools that are designed to be configured to fit the needs of electrophysiologists in various settings and for arrhythmia treatments.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.